Alembic sells Baddi formulations plant to Scott Edil Pharmacia

By Gareth Macdonald

- Last updated on GMT


Related tags Pharmacology

Alembic Pharmaceuticals Limited has sold its drug plant in Baddi, Himachal Pradesh to Scott Edil Pharmacia Limited.

The sale​ was announced in a Bombay Stock Exchange (BSE) filing last week. Alembic said the formulations plant was divested on a “slump sale basis​,” meaning that Chandigarh-based Scott Edil paid a lump sum.

Alembic – which generated revenue of INR31.34bn ($490m) in the 12 months ended March 31​ - also revealed the Baddi plant had made an “insignificant” contribution to its sales in fiscal 2016.

According to its website, Scott Edil Pharmacia operates a manufacturing facility and an R&D facility in Baddi.


News of the facility sale comes a few weeks​ after Alembic inaugurated a drug manufacturing plant in Panelav, Gujarat. 

According to Alembic, the Panelav facility will supply international markets with generic drugs.

The firm also said it will cater for domestic demand at a facility it set up in Namthang, Sikkim.

A number of drug companies have set up manufacturing facilities in Sikkim​ in recent years.

In 2007, the Indian Government said manufacturers which set up in the region before April 2017 would not have to pay taxes on revenues generated by products made there for 10 consecutive years.

Alembic set its plant up in 2014 joining peers Cipla, Sun Pharma, Zydus Cadila, IPCA, Alkem Lab, Intas Pharma, Torrent Pharma and Unichem which all operate facilities in the state.

Related news

Show more

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

Follow us